Format

Send to

Choose Destination
Thorax. 2018 Oct;73(10):918-925. doi: 10.1136/thoraxjnl-2017-211323. Epub 2018 Jul 31.

Randomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis.

Author information

1
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
2
Integrated Critical Care Unit, Sunderland Royal Hospital, Sunderland, UK.
3
Intensive Care Unit, Queen Elizabeth Hospital, Gateshead, UK.
4
Intensive Care Unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
5
Intensive Care Unit, Freeman Hospital, Newcastle upon Tyne, UK.
6
Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.
7
Department of Medicine, University of Cambridge, Cambridge, UK.
8
Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK.
9
Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.
10
Division of Anaesthesia, University of Cambridge, Cambridge, UK.
#
Contributed equally

Abstract

BACKGROUND:

Critically ill patients with impaired neutrophil phagocytosis have significantly increased risk of nosocomial infection. Granulocyte-macrophage colony-stimulating factor (GM-CSF) improves phagocytosis by neutrophils ex vivo. This study tested the hypothesis that GM-CSF improves neutrophil phagocytosis in critically ill patients in whom phagocytosis is known to be impaired.

METHODS:

This was a multicentre, phase IIa randomised, placebo-controlled clinical trial. Using a personalised medicine approach, only critically ill patients with impaired neutrophil phagocytosis were included. Patients were randomised 1:1 to subcutaneous GM-CSF (3 μg/kg/day) or placebo, once daily for 4 days. The primary outcome measure was neutrophil phagocytosis 2 days after initiation of GM-CSF. Secondary outcomes included neutrophil phagocytosis over time, neutrophil functions other than phagocytosis, monocyte HLA-DR expression and safety.

RESULTS:

Thirty-eight patients were recruited from five intensive care units (17 randomised to GM-CSF). Mean neutrophil phagocytosis at day 2 was 57.2% (SD 13.2%) in the GM-CSF group and 49.8% (13.4%) in the placebo group, p=0.73. The proportion of patients with neutrophil phagocytosis≥50% at day 2, and monocyte HLA-DR, appeared significantly higher in the GM-CSF group. Neutrophil functions other than phagocytosis did not appear significantly different between the groups. The most common adverse event associated with GM-CSF was fever.

CONCLUSIONS:

GM-CSF did not improve mean neutrophil phagocytosis at day 2, but was safe and appeared to increase the proportion of patients with adequate phagocytosis. The study suggests proof of principle for a pharmacological effect on neutrophil function in a subset of critically ill patients.

KEYWORDS:

bacterial infection; gm-csf; neutrophil biology

PMID:
30064991
PMCID:
PMC6166597
DOI:
10.1136/thoraxjnl-2017-211323
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center